Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.62 |
| ▸ | GAA | P10253 | 6/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.62 |
| ▸ | HPGD | P15428 | 4/20 | 0.62 |
| ▸ | MAPT | P10636 | 4/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.60 |
| ▸ | CFTR | P13569 | 1/20 | 0.56 |
| ▸ | NOS2 | P35228 | 1/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | CASP1 | P29466 | 1/20 | 0.51 |
| ▸ | CASP7 | P55210 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5100210 | 0.98 | ALDH1A1 (0.60) | KDM4EALDH1A1GAAHSD17B10HPGD | |
| SCHEMBL29009329 | 0.89 | NOS2 (0.52) | KDM4EALDH1A1GAAHSD17B10HPGD | |
| SCHEMBL858839 | 0.85 | ALDH1A1 (0.66) | KDM4EALDH1A1GAAHSD17B10HPGD | |
| SCHEMBL26800292 | 0.84 | KDM4E (0.57) | KDM4EALDH1A1GAAHSD17B10HPGD | |
| SCHEMBL3720784 | 0.84 | ALDH1A1 (0.57) | KDM4EALDH1A1GAAHSD17B10HPGD | |
| SCHEMBL30821626 | 0.83 | NOS2 (0.57) | KDM4EALDH1A1GAAHPGDMAPT | |
| SCHEMBL29923727 | 0.83 | ALDH1A1 (0.59) | KDM4EALDH1A1GAAHPGDMAPT | |
| SCHEMBL29380973 | 0.83 | SMN1; SMN2 (0.59) | KDM4EALDH1A1MAPTNOS2GLA | |
| SCHEMBL268601 | 0.83 | CA12 (0.67) | KDM4EALDH1A1GAAHSD17B10HPGD | |
| SCHEMBL27720018 | 0.83 | SMN1; SMN2 (0.59) | KDM4EALDH1A1MAPTNOS2GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 225 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-63290856-A | — | — | None | — | — | JP | disclosed |
| EP-4712958-A2 | USE OF UROLITHIN DERIVATIVES IN THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | Vandria SA (CH) | 2026-03-25 | — | — | EP | disclosed |
| US-12473269-B2 | Urolithin derivatives and methods of use thereof | VANDRIA SA (CH) | 2025-11-18 | — | — | US | disclosed |
| US-12358884-B2 | Urolithin derivatives and methods of use thereof | VANDRIA SA (CH) | 2025-07-15 | — | — | US | disclosed |
| US-12351567-B2 | Urolithin derivatives and methods of use thereof | VANDRIA SA (CH) | 2025-07-08 | — | — | US | disclosed |
| EP-4561556-A2 | THERAPEUTIC USES OF UROLITHIN DERIVATIVES | Vandria SA (CH) | 2025-06-04 | — | — | EP | disclosed |
| CN-115677601-B | Compound with anti-tumor activity and application thereof | 石药集团中奇制药技术（石家庄）有限公司 | 2025-06-03 | — | — | CN | disclosed |
| CN-119947717-A | Therapeutic use of urolithin derivatives | 范徳利亚股份公司 | 2025-05-06 | — | — | CN | disclosed |
| CN-119912402-A | FTO inhibitor and preparation method and application thereof | 中国科学院上海药物研究所 | 2025-05-02 | — | — | CN | disclosed |
| CN-119874668-A | Main protease regulator and application thereof | 北京昌平实验室 | 2025-04-25 | — | — | CN | disclosed |
| US-4191840-A | Oxamic acid derivatives | AMERICAN HOME PRODUCTS CORPORATION (US) | 1980-03-04 | — | — | US | disclosed |
| EP-0006114-A1 | 7-Methoxy-5-oxo-5H-thiazolo(2,3-b)quinazolin-2-carboxylic acid and its pharmaceutically acceptable salts, process for their preparation and medicines containing them | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1980-01-09 | — | — | EP | disclosed |
| US-4160100-A | OXAMIC ACID DERIVATIVES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1979-07-03 | — | — | US | disclosed |
| US-4154961-A | Oxamic acid derivatives | AMERICAN HOME PRODUCTS CORPORATION (US) | 1979-05-15 | — | — | US | disclosed |
| US-4069343-A | OXAMIC ACID DERIVATIVES FOR THE PREVENTION OF IMMEDIATE TYPE HYPERSENSITIVITY REACTIONS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1978-01-17 | — | — | US | disclosed |
| US-4054661-A | Pyridyl oxamic acid derivatives and use in the prevention of allergic reactions | AMERICAN HOME PRODUCTS CORPORATION (US) | 1977-10-18 | — | — | US | disclosed |
| US-4054657-A | Pyrimidinyl oxamic acids and esters, and compositions and methods for the suppression of allergic manifestations | AMERICAN HOME PRODUCTS CORPORATION (US) | 1977-10-18 | — | — | US | disclosed |
| US-4054666-A | Compositions and methods of treating immediate hypersensitivity reactions with thiazolyl oxamic acid derivatives | AMERICAN HOME PRODUCTS CORPORATION (US) | 1977-10-18 | — | — | US | disclosed |
| US-4036837-A | 2 Alkoxyoxamoyl-pyrazines | AMERICAN HOME PRODUCTS CORPORATION (US) | 1977-07-19 | — | — | US | disclosed |
| US-3966965-A | Oxamic acid derivatives for the prevention of immediate type hypersensitivity reactions | AMERICAN HOME PRODUCTS CORPORATION (US) | 1976-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12358884-B2 | Urolithin derivatives and methods of use thereof | NLN, UQCRC2, TUFM | KDM4E 4333/4885ALDH1A1 851/4885GAA 279/4885 |
| US-12351567-B2 | Urolithin derivatives and methods of use thereof | NLN, UQCRC2, TUFM | KDM4E 4333/4885ALDH1A1 851/4885GAA 279/4885 |
| US-12473269-B2 | Urolithin derivatives and methods of use thereof | NLN, UQCRC2, TUFM | KDM4E 4333/4885ALDH1A1 851/4885GAA 279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.